Logo for Oculis Holding AG

Oculis Holding AG Investor Relations Material

Latest events

Logo for Oculis Holding AG

R&D Day 2025

Oculis Holding AG
Logo for Oculis Holding AG

R&D Day 2025

15 Apr, 2025
Logo for Oculis Holding AG

Q4 2024

11 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Oculis Holding AG

Access all reports
Oculis Holding AG is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's product pipeline includes several advanced-stage candidates designed to address significant unmet needs in ophthalmology. Notable among these are OCS-01, a topical eye drop for diabetic macular edema and post-cataract surgery inflammation, OCS-02, a topical biologic targeting dry eye disease and uveitis, and OCS-05, aimed at neuro-ophthalmic conditions such as acute optic neuritis and glaucoma. The company is headquartered in Zug, Switzerland, and its shares are listed on the Nasdaq.